Clinical Trials Logo

Chronic Plaque Psoriasis clinical trials

View clinical trials related to Chronic Plaque Psoriasis.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT01200264 Withdrawn - Clinical trials for Chronic Plaque Psoriasis

Apremilast for Chronic Plaque Psoriasis (CPP) Patients Who Have Failed One Course of Biologic Therapy

Start date: September 2010
Phase: Phase 2
Study type: Interventional

This is a Phase II, open label, investigator-initiated study to be done at Duke University Medical Center to treat adult patients (ages 18-80) with chronic plaque psoriasis who have failed Biologic Therapy with Apremilast 30 mg BID for 24 weeks. At the time of enrollment, the patient must have received biologic therapy without achieving a response of "almost clear" or "clear" according to PGA or has not responded with a 75% reduction of PASI score. Once deemed eligible, subjects will return for a baseline visit and receive Apremilast therapy and instructions. Subjects will be treated at weeks 0,4,8,12,16,20 and 24; subjects will be evaluated 28 days after last dose of Apremilast for safety and efficacy.